It is more so a combination of factors including diet, hormone imbalances, lack of sleep, nutrient imbalances, and immune system disparities
An open-label approach was considered acceptable as the PK endpoints were not judged to be affected by knowledge of treatment allocation
Josh Cohen, co-CEO of Amylyx, said the company plans to get the Phase III data by 2026 and to go to market by 2027
Yes, and some researchers prefer this approach, especially at higher doses (8mg and 12mg)
[5] [6] No published randomized trial has tested microdose schedules
They contend that clear statutory standards and regulatory oversight can help mitigate some risks associated with sports wagering by incorporating responsible gaming measures and funding support services